Authors: M P Yavropoulou N A T Hamdy S E Papapoulos
Publish Date: 2013/02/23
Volume: 24, Issue: 8, Pages: 2353-2357
Abstract
We addressed the question whether the response of osteoporotic patients to bisphosphonate treatment is reduced with time Bisphosphonatetreated women with postmenopausal or glucocorticoidinduced osteoporosis showed adequate and consistent changes of bone markers to subsequently administered intravenous pamidronate Response of osteoporotic patients to bisphosphonates is not impaired during their longterm administrationTwenty one women with postmenopausal osteoporosis PMO aged 68 ± 82 years and 14 women with glucocorticoidinduced osteoporosis GIOP aged 65 ± 10 years were treated with trimonthly intravenous infusions of 45 mg of pamidronate for 1 year All patients had been previously treated with bisphosphonates alendronate risedronate pamidronate for a mean period of 62 years range 13–14 years Blood samples were taken for measurement of the bone resorption marker Cterminal crosslinking telopeptide of type I collagen CTXI on days 1 and 4 and of the bone formation marker procollagen type I N propeptide P1NP on day 1 of every trimonthly treatment courseWith each treatment course there was a significant decrease in serum CTXI on day 4 and an increase to baseline values 3 months after each infusion in both PMO mean values day 1 29133 ± 16078 pg/ml vs day 4 131 ± 917 pg/ml p 0001 and GIOP day 1 2193 ± 1148 pg/ml vs day 4 988 ± 516 pg/ml p 0001 Serum P1NP remained stable during the whole year of treatmentLongterm bisphosphonate treatment of women with either PMO or GIOP does not impair the response to subsequently administered intravenous pamidronate suggesting that inadequate response to longterm bisphosphonate treatment is not responsible for treatment failure
Keywords: